Drug delivery techniques for treating age-related macular degeneration
Authors:
- Ingrid U ScottISIngrid U Scott
- Harry W FlynnHFHarry W Flynn
- 5 October 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 11 (1) , 61-68
Abstract
Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections. Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles. Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.Keywords
This publication has 66 references indexed in Scilit:
- Design and in Vitro Biocompatibility of a Novel Ocular Drug Delivery DeviceJournal of Functional Biomaterials, 2013
- Targeted Administration into the Suprachoroidal Space Using a Microneedle for Drug Delivery to the Posterior Segment of the EyeInvestigative Ophthalmology & Visual Science, 2012
- Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007American Journal of Ophthalmology, 2011
- Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat ModelJournal of Ocular Pharmacology and Therapeutics, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseasesDrug Delivery and Translational Research, 2010
- A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- The potential of nanomedicine therapies to treat neovascular disease in the retinaJournal of Angiogenesis Research, 2010
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006